CCL22 and neoplasm: Combination of GDC‐0449 and VS‐4718 could induce significantly synergistic inhibitory effect on CCL22‐stimulated tumor growth (Figure 6A) and those aforementioned tumor‐promoting biomarkers in indicated tumors (Figure 6B–D).